Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

The company's shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。